HOME


PAST DIGITAL ISSUES


HIV/AIDS HOTLINES


HIV 101


POSITIVE PROFILES


ASO SPOTLIGHT


RECENT ARTICLES


HOW TO PAY FOR HIV TREATMENT AND MEDICATIONS


ADAP CRITERIA AND FORMULARIES


ASO LISTINGS


REVIEW OF HIV MEDICATIONS


2017 HIV/AIDS FUNDRAISING ACTIVITIES & EVENTS


ABOUT HIV POSITIVE! MAGAZINE


LINKS


SUBSCRIBE


CONTACT US


ADVERTISER INFORMATION

Entry Inhibitor

This class of drug is meant to interfere with the entry, fusion or binding of the HIV virus to a healthy cell.


SELZENTRY

(Maraviroc)

DHHS Status: Not recommended, other

Manufacturer: Viiv Healthcare (www.viivhealthcare.com)
Selzentry (www.selzentry.com)

FDA approval date: August 7, 2006

Financial Assistance: https://www.viivhealthcareforyou.com

Selzentry is available in 150 and 300mg tablets, and must be taken twice a day. There is no “standard” dose for Selzentry. The dosing varies depending on which other medications you take with it.

Review: Selzentry is the first in the class of entry inhibitors. It stops HIV from entering your cells using the CCR5 receptor. Unfortunately, it does not work against strains of the virus that use another receptor called CXCR4. You should have a “tropism assay” done before taking Selzentry to see if the drug will work for you. This testing is expensive but there can be financial assistance available through ViiV.



Single Tablet Regimens

Protease Inhibitors

Nucleoside Reverse Transcriptase Inhibitors

Non-Nucleoside Reverse Transcriptase Inhibitors

Fusion Inhibitor

Entry Inhibitor

Integrase Inhibitor

Pharmacokinetic Enhancer

 




 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 



Copyright 2017, Positive Health Publications, Inc.

This magazine is intended to enhance your relationship with your doctor - not replace it! Medical treatments and products should always be discussed with a licensed physician who has experience treating HIV and AIDS!